Keros Therapeutics (NASDAQ:KROS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Keros Therapeutics (NASDAQ:KROS) from a strong sell rating to a hold rating in a research report released on Monday morning,Wall Street Zen reports.

KROS has been the topic of a number of other reports. Zacks Research raised Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 27th. Leerink Partners reduced their price objective on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Wells Fargo & Company dropped their target price on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Keros Therapeutics in a research report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Keros Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Keros Therapeutics Trading Up 2.3%

Shares of KROS stock opened at $9.54 on Monday. The firm has a fifty day simple moving average of $11.08 and a 200-day simple moving average of $11.77. The company has a market capitalization of $187.21 million, a PE ratio of -3.38 and a beta of 1.13. Keros Therapeutics has a twelve month low of $8.98 and a twelve month high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $1.66. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.85%. The firm had revenue of $40.01 million for the quarter, compared to the consensus estimate of $14.76 million. Equities research analysts predict that Keros Therapeutics will post -3.81 EPS for the current year.

Keros Therapeutics announced that its board has authorized a stock repurchase plan on Wednesday, September 9th that allows the company to repurchase $5 million in outstanding shares. This buyback authorization allows the company to buy up to 2.3% of its shares through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

Insiders Place Their Bets

In other Keros Therapeutics news, insider Lorena Raquel Lerner sold 3,568 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total transaction of $36,714.72. Following the sale, the insider directly owned 27,559 shares of the company’s stock, valued at approximately $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 5,343 shares of company stock worth $54,985 in the last three months. 12.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in Keros Therapeutics during the 2nd quarter valued at about $29,898,000. Nantahala Capital Management LLC purchased a new position in Keros Therapeutics in the 2nd quarter worth about $15,091,483. Dimensional Fund Advisors LP raised its holdings in Keros Therapeutics by 453.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company’s stock worth $3,547,000 after buying an additional 263,347 shares during the period. ADAR1 Capital Management LLC purchased a new stake in Keros Therapeutics during the second quarter valued at about $2,641,000. Finally, Man Group plc purchased a new position in Keros Therapeutics during the 2nd quarter worth approximately $1,664,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Key Stories Impacting Keros Therapeutics

Investors following KROS have been watching these stories:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $20 price target, and raised its FY2026 and FY2027 earnings estimates, including a notably smaller projected FY2027 loss. A Zacks analysis also cited oversold technical conditions and improving analyst earnings estimates as possible ingredients for a turnaround. Zacks turnaround analysis
• Neutral Sentiment: A report described a large increase in short interest but listed short interest at zero shares and a zero-day short-interest ratio, so the figures provide no clear indication of meaningful short pressure.
• Negative Sentiment: Despite raising some near-term estimates, HC Wainwright cut its FY2028, FY2029 and FY2030 forecasts; the company is still expected to post losses in those periods, underscoring ongoing earnings uncertainty.

About Keros Therapeutics

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-?) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function. Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.